EU/3/19/2225

About

On 13 November 2019, orphan designation EU/3/19/2225 was granted by the European Commission to IDEA Innovative Drug European Associates (Ireland) Limited, Ireland, for replication-incompetent, non-integrating, herpes simplex virus 1 vector expressing the human transglutaminase-1 enzyme for the treatment of autosomal recessive congenital ichthyosis.

Key facts

Active substance
Replication-incompetent, non-integrating, herpes simplex virus 1 vector expressing the human transglutaminase-1 enzyme
Disease / condition
Treatment of autosomal recessive congenital ichthyosis
Date of first decision
13/11/2019
Outcome
Positive
EU designation number
EU/3/19/2225

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product it it is approved for marketing authorisation.

Sponsor's contact details

IDEA Innovative Drug European Associates (Ireland) Limited
13 Classon House
Dundrum Business Park, Dundrum
Dublin, D14 W9Y3
Ireland
Tel. + 353 1903 6117
E-mail:  inquires@krystalbio.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating